Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breast cancer survivors get tested: does vaginal estrogen raise risks?

NCT ID NCT00984399

First seen Jan 02, 2026 · Last updated May 20, 2026 · Updated 19 times

Summary

This study looked at whether a low-dose vaginal estrogen tablet (Vagifem) is safe for women who have had breast cancer and are taking hormone-blocking drugs called aromatase inhibitors. 31 postmenopausal women with a history of breast cancer used the tablet for vaginal dryness, and researchers measured their blood estrogen levels over 12 weeks. The goal was to see if the estrogen gets absorbed into the bloodstream enough to potentially raise the risk of cancer recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital

    Sleepy Hollow, New York, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States

Conditions

Explore the condition pages connected to this study.